Denali Therapeutics Inc. (NASDAQ:DNLI) revealed topline results from an analysis of Regimen G of the Phase 2/3 HEALEY ALS ...

This article was published by IBN, a multifaceted communications organization engaged in connecting public companies to the ...

Eli Lilly partnership aims to identify new treatments for ALS based on antibodies from people with very slow disease ...

Announcing a new publication for Acta Materia Medica journal. Complex biological mechanisms and unidentified therapeutic targets for amyotrophic lateral sclerosis (ALS) significantly hinder the develo ...

Denali Therapeutics Inc.'s stock remains stable despite trial setback in ALS. BLA filing for MPS II treatment on track. Click ...

When a renowned Israeli TV journalist lost his ability to speak clearly because of ALS, he thought his career might be over.

Acetylcysteine zidrimer is under clinical development by Orpheris and currently in Phase II for Amyotrophic Lateral Sclerosis.

Central Nervous System Disorders is under clinical development by Neuroplast and currently in Phase I for Amyotrophic Lateral Sclerosis.

Misses from amyotrophic lateral sclerosis hopefuls Denali Therapeutics and partners AbbVie and Calico Life Sciences mark the ...

Plus, Healthy Minds Project, the Trevor Project, and the University of Montana received big gifts to support mental health services, advocacy, and youth in crisis.